At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
CPC-201drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc·interventional·Posted Jul 9, 2014·Updated Jun 4, 2020
In Brief
A Phase 2 clinical trial evaluating CPC-201 for Alzheimer's Disease. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartJul 2014
Primary CompletionJul 2016
TodayJul 2026
First PostedJul 9, 2014
Enrollment StartJul 31, 2014
Primary CompletionJul 31, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.0 years ago
Interventions
CPC-201drug